單核吞噬細(xì)胞系統(tǒng)包括單核細(xì)胞推進高水平、結(jié)締組織和淋巴組織中的巨噬細(xì)胞、骨組織中的破骨細(xì)胞技術先進、神經(jīng)組織中的小膠質(zhì)細(xì)胞進入當下、肝庫(kù)弗細(xì)胞調整推進、皮膚朗格漢斯細(xì)胞和肺巨噬細(xì)胞完善好。單核吞噬細(xì)胞系統(tǒng)能吞噬清除體內(nèi)病菌異物及衰老傷亡細(xì)胞服務體系，參與非特異性免疫防御機(jī)制多種，參與特異性免疫應(yīng)答指導，發(fā)揮特異性免疫功能等廣泛認同，是人體中重要的一類保護(hù)性細(xì)胞系統(tǒng)。

1流動性、單核細(xì)胞：?jiǎn)魏思?xì)胞是白細(xì)胞中體積較大的一種鍛造，在機(jī)體發(fā)生炎癥時(shí)進(jìn)入組織內(nèi)，分化為具有活躍吞噬功能的巨噬細(xì)胞持續創新；

2改善、巨噬細(xì)胞：巨噬細(xì)胞廣泛分布于各器官內(nèi)空白區，尤其多見(jiàn)于淋巴結(jié)、脾信息化、肝形勢、骨髓等器官。具有活躍的吞噬能力取得明顯成效，可識(shí)別吞噬細(xì)菌約定管轄、異物、壞死組織等創新的技術，是機(jī)體內(nèi)有重要防御功能的細(xì)胞發揮；

3、破骨細(xì)胞：破骨細(xì)胞是骨吸收的主要功能細(xì)胞快速增長，在吸收骨質(zhì)時(shí)具有將基質(zhì)中的鈣離子持續(xù)轉(zhuǎn)移至細(xì)胞外液的特殊功能開放以來，在骨發(fā)育、生長(zhǎng)高質量、修復(fù)提供了有力支撐、重建中具有重要作用；

4前景、小膠質(zhì)細(xì)胞：小膠質(zhì)細(xì)胞是腦組織中的神經(jīng)免疫細(xì)胞意見征詢，具有吞噬功能，同時(shí)能促進(jìn)神經(jīng)系統(tǒng)的發(fā)育大大提高，促進(jìn)神經(jīng)元的存活；

5再獲、肝庫(kù)弗細(xì)胞：肝巨噬細(xì)胞是肝內(nèi)的巨噬細(xì)胞產品和服務，能清除從門靜脈入肝的抗原異物，清除衰老的血細(xì)胞和監(jiān)視腫瘤體驗區；

6增多、肺巨噬細(xì)胞：肺巨噬細(xì)胞是參與肺防御免疫功能的重要細(xì)胞之一，具有活躍的吞噬功能有望，能吞噬吸入的塵粒進一步推進、細(xì)菌、異物及滲出的紅細(xì)胞方案。

對(duì)于淋巴結(jié)巨噬細(xì)胞的研究應用的選擇，體內(nèi)實(shí)驗(yàn)時(shí)，我們會(huì)使用荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸鹽脂質(zhì)體左右。如果研究的是實(shí)驗(yàn)性淋巴絲蟲(chóng)病模型背景下，可以參考如下文獻(xiàn)。

論文題目： Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor–mediated lymphangiogenesis

期刊名稱：J Clin Invest.

時(shí)間期卷：2021;131(5):e140853.

在線時(shí)間：2021年1月12日

DOI：doi.org/10.1172/JCI140853.

品牌：Liposoma

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品名：Clodronate Liposomes  and Control Liposomes

注射方式：s.c.皮下

濃度：2.5mg/ml

次數(shù)：2次

頻率：3天一次

To interrogate the functional role of prolymphangiogenic monocytes and monocyte-derived MΦs recruited to the site of filaria-parasitized lymphatics, we blocked CCR2+ monocyte recruitment following BmL3 infection by administration of an anti-CCR2 ablating antibody (28). In a complementary approach, we reduced total phagocyte cell populations, including monocytes and MΦs, by local subcutaneous administration of clodronate encapsulated in liposomes (Figure 7A). Confirming treatment efficacy, both anti-CCR2 and clodronate liposome treatments delivered to filaria-infected mice successfully reduced circulating blood monocyte populations. Further, anti-CCR2 significantly reduced lymphatic-associated monocyte populations following infection (Figure 7, B and C). Following ablations of monocyte and total phagocyte populations, while remodeled lymphatics were still apparent, the magnitude of lymphatic insufficiency was significantly reduced, as demonstrated by reduced backflow of ICG following anti-CCR2 treatment (Figure 7, F and G) and dermal retention of EB (Figure 7H) following both anti-CCR2 and clodronate liposome treatments. Additionally, dermal lymphatic vessel dilation was significantly reduced following both anti-CCR2 and clodronate liposome treatments (Figure 7, I and J). These ablation experiments indicate a functional role for prolymphangiogenic monocyte populations, after recruitment from the blood to local parasitized lymphatics, in the development of filaria-associated lymphatic dysfunction.

材料和方法：

CCR2 and clodronate liposome monocyte/MΦ depletion experiments.

Following infection, mice were administered either 20 μg MC-21 rat anti–mouse CCR2 depleting antibody (Matthias Mack, Regensburg University; ref. 28) i.p., daily, or 2.5 mg/mL clodronate liposome suspensions (Liposoma) s.c. at BmL3 infection sites every 3 days. Treatment was undertaken for 6 days.